Oncotelic Therapeutics, Inc. (OTCQB: OTLC) reported its first-quarter 2026 financial results and provided a corporate update highlighting continued advancement across its oncology, AI-enabled drug development, and advanced drug delivery initiatives. The company also noted progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform.
According to the press release, Oncotelic maintained the previously established fair value of approximately $388 million for its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while continuing to pursue capital-efficient growth across its diversified biotechnology platform.
The company is a clinical-stage biopharmaceutical firm focused on developing oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
Oncotelic leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, the company licenses and co-develops select drug candidates through strategic partnerships and joint ventures. It currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
The full press release is available at https://ibn.fm/DTVsF. For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC.
